CSP 553 - adjuvant therapy in prostate carcinoma treatment (CAP).
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Docetaxel (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CAP
- 01 May 2020 Status changed to discontinued
- 05 Oct 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 04 Sep 2012 Planned end date changed from 1 Jun 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.